Bayer Pharma AG v. Lupin Limited: Rivaroxaban Patent Infringement Case Dismissed in Delaware

Case Overview

When pharmaceutical giants file patent infringement actions in Delaware, the pharmaceutical and IP communities take notice. In *Bayer Pharma AG v. Lupin Limited* (Case No. 1:21-cv-00314), Bayer Pharma AG initiated a patent infringement action in the U.S. District Court for the District of Delaware on March 1, 2021, targeting generic pharmaceutical manufacturer Lupin Limited over its alleged infringement of patent US10828310B2 — a patent covering the blockbuster anticoagulant XARELTO® (rivaroxaban) at the 2.5 mg dosage.

The case ultimately concluded on January 28, 2026, with a stipulated dismissal — a procedural resolution that carries significant strategic implications for pharmaceutical patent litigation, Hatch-Waxman ANDA disputes, and branded drug exclusivity enforcement. For patent attorneys, IP professionals, and R&D leaders navigating the increasingly competitive generic drug landscape, this case offers critical lessons in litigation strategy, settlement dynamics, and pharmaceutical patent risk management.

The Parties

The Patent at Issue

This landmark case involved U.S. Patent **US10828310B2** (Application No. US16/264032), covering formulations and methods of use related to **2.5 mg rivaroxaban**, the specific low-dose presentation of XARELTO® indicated for reducing thrombotic cardiovascular risks in patients with chronic coronary artery disease or peripheral arterial disease, often used in combination with aspirin.

• • US10828310B2 — 2.5 mg Rivaroxaban formulation and methods of use

The Verdict & Legal Analysis

Outcome

The case concluded via a stipulated dismissal entered pursuant to Federal Rules of Civil Procedure Rules 41(a)(1) and 41(c). Per the stipulation:

• Plaintiffs’ claims against Teva (noted in the dismissal record alongside Lupin) were dismissed with prejudice.
• Teva’s counterclaims against Plaintiffs were dismissed without prejudice.
• All parties agreed to bear their own costs, disbursements, and attorneys’ fees.

The dismissal order references Teva Pharmaceuticals USA, Inc. alongside the original Lupin Limited defendant, suggesting the litigation may have been consolidated or amended to include multiple generic defendants — a common practice in Hatch-Waxman multi-defendant proceedings. Specific damages amounts were not publicly disclosed.

Legal Significance

The underlying cause of action was patent infringement — specifically, Bayer’s assertion that Lupin’s (and Teva’s) generic 2.5 mg rivaroxaban ANDA filing constituted infringement of US10828310B2 under the Hatch-Waxman framework. Under this framework, the mere filing of an ANDA with a Paragraph IV certification constitutes a technical act of infringement sufficient to trigger litigation, even before any generic product reaches market.

The stipulated dismissal — with prejudice as to plaintiffs’ claims — strongly suggests a negotiated resolution, likely involving a settlement agreement with confidential licensing or market entry terms. The asymmetric dismissal structure (plaintiffs’ claims dismissed with prejudice; defendant’s counterclaims dismissed without prejudice) is a hallmark of negotiated Hatch-Waxman settlements, where generic manufacturers often preserve invalidity counterclaim rights in exchange for agreed-upon future market entry dates.

The case reinforces several important dynamics in pharmaceutical patent litigation:

1. Hatch-Waxman Settlement Architecture: The with-prejudice/without-prejudice dismissal structure reflects established settlement patterns where brand manufacturers grant authorized generic licenses or delayed entry agreements in exchange for litigation resolution.
2. Delaware as Pharmaceutical Patent Forum: This case affirms Delaware’s continued dominance as the preferred venue for brand-versus-generic pharmaceutical patent disputes, particularly for large-cap pharmaceutical patent portfolios.
3. Low-Dose Formulation Patents as Distinct Assets: The isolation of the 2.5 mg rivaroxaban formulation in a separate patent (US10828310B2) — distinct from higher-dose XARELTO® formulations — illustrates sophisticated pharmaceutical patent prosecution strategy aimed at maximizing portfolio coverage across dosage-specific indications.